GuidelineArthritis & rheumatology (Hoboken, N.J.)2019
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.
Guideline in Arthritis & rheumatology (Hoboken, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05540743 (The Efficacy of Anti-TNF Alpha Agents in the Treatment of JIA- Associated Uveitis in a Pediatric Cohort), which is not on this map. Cited by 38 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy of Anti-TNF Alpha Agents in the Treatment of JIA- Associated Uveitis in a Pediatric Cohort
Who cites it
38 citing papers in PubMed, 7 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Exploring microRNA signatures in pediatric non-infectious uveitis: meta-analysis and molecular profiling of patient samples.Journal of applied genetics · 2025Pooled it
- The incidence and risk factors of uveitis in children with juvenile idiopathic arthritis (JIA): a meta -analysis and literature review.Pediatric rheumatology online journal · 2025Pooled it
- Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis.The Cochrane database of systematic reviews · 2022Pooled it
- 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis.Arthritis care & research · 2022Guideline
- 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging.Arthritis & rheumatology (Hoboken, N.J.) · 2022Guideline
- 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2022Guideline
- American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1.Arthritis & rheumatology (Hoboken, N.J.) · 2020Guideline
- Oligoarticular juvenile idiopathic arthritis: epidemiological, clinical, therapeutic and outcome profile of a Tunisian cohort.BMC pediatrics · 2026Article
- Renal involvement in different subtypes of children with juvenile idiopathic arthritis: results from a single-center cohort.Clinical rheumatology · 2026Article
- The ADJUST trial and its implications for biologic discontinuation in juvenile idiopathic arthritis-associated uveitis.Eye (London, England) · 2026Article
- Systemic Immunomodulatory Therapy, Anterior Chamber Inflammation, and the Use of Topical Corticosteroids in Juvenile Idiopathic Arthritis-Associated Uveitis: A Long-Term Real-Life Observational Study.Journal of clinical medicine · 2026Article
- Community engagement in health guidelines and other normative products: a methodological review.Bulletin of the World Health Organization · 2025Review
- Juvenile idiopathic arthritis during 20 years in Sweden: Characteristics of children, therapy interventions, occurrence of uveitis and ocular complications.Acta ophthalmologica · 2025Article
- Treatment outcomes of a Swiss non-infectious paediatric uveitis cohort: retrospective study over ten years.Journal of ophthalmic inflammation and infection · 2025Article
- Predictors of lack of response to methotrexate in juvenile idiopathic arthritis associated uveitis.Rheumatology (Oxford, England) · 2025Article
- The management of adult and paediatric uveitis for rheumatologists.Nature reviews. Rheumatology · 2024Review
- Diagnosis and Treatment of Uveitis in Children: A Summary of the Latest Data from a 5-Year Literature Review (2018-2023).Journal of clinical medicine · 2024Review
- The Efficacy of Adalimumab in Children with Chronic Non-infectious Posterior Uveitis and Panuveitis: A Retrospective Cohort Study.Ophthalmology and therapy · 2024Article
- Article
- A clearer vision: insights into juvenile idiopathic arthritis-associated uveitis.Proceedings (Baylor University. Medical Center) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 18 institutions in 2 countries.
Funding
Abstract
objectiveTo develop recommendations for the screening, monitoring, and treatment of uveitis in children with juvenile idiopathic arthritis (JIA).
methodsPediatric rheumatologists, ophthalmologists with expertise in uveitis, patient representatives, and methodologists generated key clinical questions to be addressed by this guideline. This was followed by a systematic literature review and rating of the available evidence according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology. A group consensus process was used to compose the final recommendations and grade their strength as conditional or strong.
resultsDue to a lack of literature with good quality of evidence, recommendations were formulated on the basis of available evidence and a consensus expert opinion. Regular ophthalmic screening of children with JIA is recommended because of the risk of uveitis, and the frequency of screening should be based on individual risk factors. Regular ophthalmic monitoring of children with uveitis is recommended, and intervals should be based on ocular examination findings and treatment regimen. Ophthalmic monitoring recommendations were strong primarily because of concerns of vision-threatening complications of uveitis with infrequent monitoring. Topical glucocorticoids should be used as initial treatment to achieve control of inflammation. Methotrexate and the monoclonal antibody tumor necrosis factor inhibitors adalimumab and infliximab are recommended when systemic treatment is needed for the management of uveitis. The timely addition of nonbiologic and biologic drugs is recommended to maintain uveitis control in children who are at continued risk of vision loss.
conclusionThis guideline provides direction for clinicians and patients/parents making decisions on the screening, monitoring, and management of children with JIA and uveitis, using GRADE methodology and informed by a consensus process with input from rheumatology and ophthalmology experts, current literature, and patient/parent preferences and values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.